10-Q: Vystar Reports Steep Revenue Decline and Widening Losses Amid Going Concern Doubts

Sentiment:

Quarterly Report 1 August 2025 12:16 PM

Vystar Corporation's latest quarterly report reveals a significant drop in revenue and a substantial increase in net loss, raising substantial doubt about its ability to continue as a going concern.

Delay expectedThe RX3000, the company's largest air purification unit, is not currently in production, with only limited samples in stock.The RX300, a smaller version of the air purification unit, is hoped to be in production in late 2025, indicating a future target rather than current availability.An even smaller air purification unit designed for automobiles and refrigerators with USB charging is hoped to be designed during 2026, indicating a long-term development timeline.

Capital raiseManagement plans to finance future operations using stock issuances to new and existing shareholders.The company received $135,000 through June 30, 2025, from shareholders who selected a conversion option for 2021 contingently convertible promissory notes, leading to the issuance of 6,750,000 shares of common stock.Received $20,000 under a separate common stock subscription agreement offered to prior note holders, with approximately 571,000 shares of common stock to be issued.Received $50,000 under a separate stock subscription agreement for 1,250,000 shares during the three months ended June 30, 2025.The company will waive its current restriction on preferred stock conversions for participating shareholders, leading to the issuance of 200,000 shares of common stock upon completion.As of June 30, 2025, $2,910,152 is included in stock subscription payable related to common stock to be issued, including 3,405,443 shares related to the 2021 contingently convertible promissory notes conversions.The company is exploring merger and acquisition opportunities, which could involve capital raising.Subsequent to the reporting period, in July 2025, the company received an additional $20,000 under a stock subscription agreement for 500,000 shares of common stock.

Worse than expectedRevenue decreased by 67.9% for the six months ended June 30, 2025, indicating a significant decline in sales performance.Gross profit decreased by 69.7% for the six months ended June 30, 2025, reflecting lower sales and higher channel costs.Net loss increased by 45.6% for the six months ended June 30, 2025, demonstrating a worsening financial bottom line.Interest expense surged by 531.3%, significantly impacting profitability due to increased debt-related costs.The company continues to operate with a substantial working capital deficit of $6.2 million and an accumulated deficit of $60.8 million, highlighting ongoing financial instability.

Summary

Revenue for the six months ended June 30, 2025, decreased by 67.9% to $24,272, down from $75,676 in the same period of 2024, primarily due to reduced sales to a former major customer.
Gross profit fell by 69.7% to $10,689 for the six months ended June 30, 2025, compared to $35,324 in the prior year, attributed to decreased sales and increased channel costs.
Net loss for the six months ended June 30, 2025, increased by 45.6% to $965,206, up from $662,859 in the comparable period of 2024.
Interest expense surged by 531.3% to $279,532 for the six months ended June 30, 2025, compared to $44,276 in 2024, mainly due to accrued interest and amortization of debt discount on related party debt issued in June 2024.
The company reported a loss on settlement of debt of $79,846 for the six months ended June 30, 2025, related to the conversion of shareholder convertible notes.
As of June 30, 2025, Vystar had cash of $22,111 and a working capital deficit of approximately $6.2 million, with an accumulated deficit of approximately $60.8 million.
Management plans to finance future operations through cash on hand, increased RxAir sales, Vytex license fees, stock issuances, and exploring merger and acquisition opportunities.
The company completed a groundbreaking RxAir prototype integrating Fluid Energy conversion technology with the Hughes Reactor in May 2025, now in final pre-production testing.
A newly redesigned website, www.vytex.com, was unveiled in July 2025 as part of a brand refresh.

Sentiment

Score: 2

Explanation: The company faces severe financial challenges, including significant revenue decline, widening losses, a substantial working capital deficit, and explicit 'going concern' doubts. While there are some positive product development updates and a legal victory, these are heavily overshadowed by the dire financial state and internal control weaknesses, indicating a very high-risk investment.

Positives

Completed a groundbreaking RxAir prototype integrating Fluid Energy conversion technology with the Hughes Reactor, advancing it to final pre-production testing.
Unveiled a newly redesigned website, www.vytex.com, in July 2025 to improve customer interaction and enhance digital presence.
Successfully defended against the EMA Financial lawsuit, with the Second Circuit Court of Appeals affirming the District Court's decision in Vystar's favor in July 2025, leading to a determination of legal fees to be awarded to Vystar.
Reduced loss from discontinued operations by 98.5% for the six months ended June 30, 2025, to $456, indicating the final winding down of Rotmans Furniture expenses.

Negatives

Revenue decreased by 67.9% to $24,272 for the six months ended June 30, 2025, compared to $75,676 in the prior year, primarily due to reduced sales to a former major customer.
Gross profit decreased by 69.7% to $10,689 for the six months ended June 30, 2025, compared to $35,324 in the prior year, driven by decreased sales and increased channel costs.
Net loss increased by 45.6% to $965,206 for the six months ended June 30, 2025, compared to $662,859 in the prior year.
Interest expense increased by 531.3% to $279,532 for the six months ended June 30, 2025, due to accrued interest and amortization of debt discount on related party debt.
Reported a working capital deficit of approximately $6.2 million and an accumulated deficit of approximately $60.8 million as of June 30, 2025.
Net cash used in operating activities increased to $140,736 for the six months ended June 30, 2025, from $80,353 in the prior year.
Identified material weaknesses in internal control over financial reporting, including lack of segregation of duties, inadequate control over transaction records, lack of controls for asset acquisition/use/disposal, lack of a formal CFO position, and lack of a functioning audit committee.

Risks

Substantial doubt exists about the company's ability to continue as a going concern due to significant losses and negative cash flow since inception.
Future operations are dependent on obtaining sufficient financing and achieving adequate revenue levels to support the cost structure.
Failure to achieve projected revenue and secure additional financing could lead to significant curtailment or reorientation of operations, potentially resulting in bankruptcy or cessation of operations.
Exposure to risks pertinent to a retailer, including the ability to acquire new customers, maintain a strong brand, and broader economic factors like interest rates and changes in customer spending patterns.
Trade policy and tariff actions by the U.S. government, including imports from China, could adversely impact growth and cost of revenue.
The future realization of net operating loss carryforwards may be subject to an annual limitation due to ownership changes under Internal Revenue Code Section 382.
Material weaknesses in internal control over financial reporting, including lack of segregation of duties, inadequate control over transaction records, and lack of a functioning audit committee, could result in material misstatements in future financial statements.

Future Outlook

Management plans to finance future operations by utilizing existing cash, increasing revenue from RxAir air purification unit sales and Vytex license fees, and issuing common stock to new and existing shareholders. The company is also exploring merger and acquisition opportunities. There is no assurance that projected revenue levels will be achieved in 2025 and beyond, and failure to secure additional financing could necessitate significant operational curtailment or cessation of operations.

Management Comments

"Management plans to finance future operations using cash on hand, increased revenue from RxAir air purification units, Vytex license fees and stock issuances to new and existing shareholders."
"The Company will also raise capital with common stock subscription issuances and is exploring merger and acquisition opportunities."
"Management expects to strengthen internal control during 2025 by developing stronger business and financial processes for accounting for transactions, which will enhance internal control for the Company."

Industry Context

Vystar operates in the air purification and natural rubber latex industries. The air purification segment, featuring RxAir products, aims to capitalize on demand for virus and bacteria destruction, a trend amplified by global health concerns. The Vytex natural rubber latex segment focuses on developing low-protein, sustainable rubber for various applications, including green tires, aligning with broader industry shifts towards eco-friendly materials. The company's efforts to combine its UV-C technology with Fluid Energy's ultrasonic technology for air and water purification indicate a strategic move towards integrated environmental solutions. However, the significant revenue decline suggests challenges in market penetration or competitive pressures within these industries.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
President	N/A	Jamie Rotman	2023-12-21	Appointment
Chief Executive Officer	N/A	Jamie Rotman	N/A	Current role, previously Steven Rotman
Chief Financial Officer	N/A	Jamie Rotman	N/A	Current role, acting CFO

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Internal Control Weakness	Lack of segregation of duties due to the small size of the Company.	2025-06-30	Could adversely affect the Company's ability to record, process, summarize and report financial information.
Internal Control Weakness	Did not maintain reasonable control over records underlying transactions necessary to permit preparation of the Company's financial statements.	2025-06-30	Could adversely affect the Company's ability to record, process, summarize and report financial information.
Internal Control Weakness	Lack of controls that provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposal of the Company's assets that could have a material effect on the financial statements.	2025-06-30	Could adversely affect the Company's ability to record, process, summarize and report financial information.
Internal Control Weakness	Lack of a formal CFO position who can devote significant attention to financial reporting resulted in multiple audit adjustments.	2025-06-30	Could adversely affect the Company's ability to record, process, summarize and report financial information.
Internal Control Weakness	Lack of a functioning audit committee, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures.	2025-06-30	Could result in a material misstatement in financial statements in future periods.

Legal Proceedings

The EMA Financial, Inc. lawsuit, alleging various breaches of a convertible promissory note and stock purchase agreement, has seen significant developments. The District Court initially ruled in Vystar's favor, finding EMA breached the note but the breach was not material, and the note balance was paid in full by Vystar. The Court granted Vystar's request for legal fees.
EMA filed a motion for reconsideration, which was denied by the Court on May 16, 2024, affirming the November 27, 2023 decision.
EMA filed a notice of appeal with the Second Circuit Court of Appeals on December 27, 2023, and Vystar filed a notice of cross-appeal on June 13, 2024.
Both parties filed their final briefs in March 2025 with the Second Circuit Court of Appeals.
On July 17, 2025, the Second Circuit Court of Appeals affirmed the District Court's decision, sending the case back to the District Court for a determination of legal fees to be awarded to Vystar.

Related Party Transactions

Jamie Rotman (President, CEO, CFO, Director): Annual compensation of $180,000 payable in Series C Preferred Stock or common stock (50% discounted), plus a $25,000 signing bonus in Series C Preferred Stock. Approximately $196,000 expensed for her employment agreement for the six months ended June 30, 2025. Has a stock subscription payable balance of $560,321 for approximately 26,204,000 shares. Also has a stock subscription payable balance of $42,047 for approximately 8,500 shares related to prior consulting services. Repaid $8,794 in related party advances in March 2025. Holds a contingently convertible promissory note with a balance of approximately $6,000.
Blue Oar Consulting, Inc. (owned by Gregory Rotman, Jamie Rotman's sister): Provides business consulting services for $15,000 per month in cash (temporarily suspended since January 2025) and $12,500 per month in shares (50% discounted). Approximately $164,000 expensed for consulting services for the six months ended June 30, 2025. Has a stock subscription payable balance of $1,014,744 for approximately 111,848,000 shares. Also has a liability of $405,000 for consulting expenses in accounts payable. Entered into a term convertible promissory note on June 1, 2024, for up to $1,000,000 at 12% interest, with a balance of approximately $727,000 at June 30, 2025, and a derivative liability of $355,981. The note's maturity was extended to January 1, 2026.
Bryan Stone (Director): Receives a $25 per unit commission for RxAir units sold to a specific customer. No commissions earned in the three and six months ended June 30, 2025. A payment of $2,348 was made in February 2025 for previously accrued commissions.
Steven Rotman (Former Officer and Director): Has a stock subscription payable balance of $427,933 for approximately 59,256,000 shares, $243,155 of reimbursable expenses payable, and $81,482 of unpaid salary. Board fees for 2021, valued at $291,000 (100,000 shares), are included in stock subscription payable, with $58,200 (20,000 shares) attributed to his balance. Has related party advances due of $77,460 from Vystar and $61,986 from Rotmans.

Stakeholder Impact

Shareholders: Face significant dilution risk from ongoing stock issuances for debt conversion, compensation, and capital raises. The substantial doubt about the company's going concern status poses a high risk to investment value. Preferred shareholders have significant liquidation preferences and contingent conversion rights.
Employees: The company's financial instability and need to potentially curtail operations could impact job security.
Creditors: Related party creditors hold significant debt, some of which is in default, and the company's liquidity issues present repayment risks.
Customers: Reduced sales to a former major customer indicate potential challenges in maintaining customer relationships or market share. The company's ability to introduce new products (RxAir) and maintain supply lines (Vytex) could be affected by financial constraints.
Suppliers: The company's financial condition and working capital deficit could pose risks to timely payments to suppliers.

Next Steps

Continue to review pricing and sales strategies in the third quarter of 2025.
Achieve projected levels of revenue in 2025 and beyond.
Obtain sufficient financing to fund planned expenses and support the cost structure.
Introduce RxAir air purification units and license Vytex NRL raw materials and foam cores to manufacturers and retailers.
File, prosecute, defend, and enforce patent claims and other intellectual property rights.
Begin production of the smaller RX300 air purification unit in late 2025.
Design an even smaller air purification unit for automobiles and refrigerators with USB charging during 2026.
Strengthen internal control during 2025 by developing stronger business and financial processes for accounting for transactions.
The EMA Financial lawsuit will return to the District Court for a determination of legal fees to be awarded to Vystar.

Key Dates

Date	Description
2013-05-02	Company began a private placement offering to sell up to 200,000 shares of 10% Series A Cumulative Convertible Preferred Stock.
2018-01-01	Shareholder contingently convertible notes payable were issued during the year ended December 31, 2018.
2018-12-31	Shareholder contingently convertible notes payable were issued during the year ended December 31, 2018.
2019-02-19	EMA Financial, Inc. filed a lawsuit against the Company in the Southern District of New York.
2019-07-18	Bernard Rotman related party note payable in the amount of $140,000 was issued in connection with the acquisition of 58% of Rotmans.
2020-01-01	Shareholder contingently convertible notes matured in January 2020.
2020-03-13	Court granted the Company's motion dismissing the first and third claims for relief in the EMA Financial lawsuit.
2020-12-31	Company received $270,000 under common stock subscription agreements for 180,000 shares during the year ended December 31, 2020.
2021-07-20	The International Latex Conference was held virtually from July 20 to 22, 2021, where Dr. Ranjit Matthan and John Heath presented.
2021-07-22	The International Latex Conference was held virtually from July 20 to 22, 2021, where Dr. Ranjit Matthan and John Heath presented.
2021-08-17	Company issued a contingently convertible promissory note totaling $5,000 to Jamie Rotman.
2021-12-31	Company issued certain contingently convertible promissory notes in varying amounts to existing shareholders which totaled $290,000 during the year ended December 31, 2021.
2022-04-11	Company amended its Articles of Incorporation to add the terms of a 10% Series B Cumulative Convertible Preferred Stock.
2022-06-24	Both parties in the EMA Financial lawsuit submitted competing motions for summary judgment.
2022-07-08	Company amended its Articles of Incorporation to add the terms of a 10% Series C Cumulative Convertible Preferred Stock.
2022-07-29	Briefing by the parties in the EMA Financial lawsuit was fully submitted.
2022-12-14	Rotmans closed its showroom.
2023-01-06	Court issued a series of preliminary rulings based upon the parties' respective summary judgment motions in the EMA Financial lawsuit.
2023-02-24	Supplemental briefing on materiality, liability, and damages in the EMA Financial lawsuit was fully briefed and submitted.
2023-03-15	Supplemental briefing on materiality, liability, and damages in the EMA Financial lawsuit was fully briefed and submitted.
2023-10-27	Court held oral argument on the issues addressed in the supplemental briefing for the EMA Financial lawsuit.
2023-11-27	Court issued its order resolving the EMA Financial case in Vystar's favor.
2023-12-21	Jamie Rotman was appointed as President of the Company.
2023-12-24	EMA filed a motion for reconsideration in the EMA Financial lawsuit.
2023-12-27	EMA filed a notice of appeal with the United States Court of Appeals for the Second Circuit regarding the EMA Financial lawsuit.
2024-01-01	Jamie Rotman's Employment Agreement was made retroactive to this date.
2024-05-16	Court held oral argument on EMA's motion for reconsideration and denied the substantive portion of its motion.
2024-06-01	Company entered into a term convertible promissory note with Blue Oar Consulting, Inc.
2024-06-13	Vystar timely filed its notice of cross-appeal in the EMA Financial lawsuit.
2024-07-22	Company entered into an Employment Agreement with Ms. Jamie Rotman.
2024-08-05	District Court denied, without prejudice to renew, the motion for attorneys fees in the EMA Financial lawsuit.
2024-09-20	EMA filed its submissions for the appeal, and Vystar requested ninety-one days to file its opposition and cross-appeal.
2024-12-15	ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, is effective for fiscal years beginning after this date.
2025-01-01	Blue Oar's term convertible promissory note maturity date can be extended to this date.
2025-01-31	Company offered two conversion options to the holders of the 2021 contingently convertible promissory notes in January 2025.
2025-02-01	Monthly installment payments of principal and interest of $7,500 to Blue Oar began.
2025-03-31	Both parties filed their final briefs in the Second Circuit Court of Appeals in March 2025.
2025-05-31	Vystar announced the completion of a groundbreaking RxAir prototype in May 2025.
2025-06-30	End of the quarterly period covered by this report.
2025-07-01	Blue Oar's term convertible promissory note balloon payment was originally due on this date, now extended to January 1, 2026.
2025-07-17	The Second Circuit Court of Appeals issued its decision, affirming the District Court's decision in the EMA Financial lawsuit.
2025-07-31	Company received $20,000 under a stock subscription agreement for 500,000 shares of common stock in July 2025.
2025-08-01	Date of filing of this Form 10-Q.
2026-01-01	Extended maturity date for Blue Oar's term convertible promissory note.

Recommendation

strong sell

Vystar Corporation's latest 10-Q filing presents a highly concerning financial picture, warranting a 'strong sell' recommendation for any seasoned investor or institution. The company reported a staggering 67.9% decline in revenue and a 45.6% increase in net loss for the six months ended June 30, 2025. This severe operational deterioration is compounded by a substantial working capital deficit of $6.2 million and an accumulated deficit exceeding $60 million, leading management to explicitly state 'substantial doubt about the Company’s ability to continue as a going concern.' While the company highlights some product development (RxAir prototype) and a legal victory, these are minor positives against a backdrop of severe financial distress, escalating interest expenses, and admitted material weaknesses in internal controls. The reliance on continuous stock issuances for financing, including significant related-party transactions, suggests a highly dilutive and unsustainable funding model. The company's future is highly speculative and dependent on uncertain financing and revenue targets, making it an extremely high-risk investment with significant downside potential.

Keywords

Vystar Corporation, RxAir, Vytex, Air Purification, Natural Rubber Latex, SEC Filing, 10-Q, Financial Results, Going Concern, Liquidity, Net Loss, Revenue Decline, Internal Controls, Related Party Transactions, Intellectual Property, Patents, Medical Devices, Bedding Products, Furniture Retail, Litigation

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.